Validation of a New Prognostic Score for Adult Patients With RAS Wild-type mCRC Treated With Vectibix® and FOLFIRI or FOLFOX in First Line (VALIDATE)

NCT03043950 · clinicaltrials.gov ↗

COMPLETED

Status

647

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Colorectal Cancer
RAS Wild-type

Interventions

DRUG: Panitumumab

Sponsor

iOMEDICO AG

Collaborators

[object Object]